Effects of the Federal Trade Commission's Repeal of Non-Compete Agreements on the Pharma Industry

FTC

Jan 25

Written By Ron Lanton

In an interview with Associate Editor Donald Tracy, MA, Ron Lanton III, Esq., Partner, Lanton Law offers his thoughts on the recent Federal Trade Commission (FTC) repeal of non-compete agreements, and how it could effect the #pharma industry.

The interview can be viewedhere.

FTCnon compete agreementspharmapharmacyFederal Trade Commission

Ron Lanton

New Presidential Executive Order on Artificial Intelligence Released

U.K. Launches It's Strategic Vision for Global Leadership and Ethical Innovation Using AI